ClinicalTrials.gg
Not yet recruitingNCT06385873Updated May 13, 2024

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

A Phase 2 interventional study of RC48 and Adebrelimab in Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, sponsored by The First Affiliated Hospital with Nanjing Medical University. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing disitamab vedotin in Stomach Neoplasms — 14 open to participants now, 17 under way, 5 of them phase 3. disitamab vedotin · Stomach Neoplasms.

Planned enrollment
16th of 22
32 · median 49
Started
2024
with 5 others
Phase 2
15 of 22
8 open now
Primary completion
2027-05
later than 12 of 16 live
Registered
17th of 22
by date
Lead sponsor
1 of 22
The First Affiliated Hospital with Nanjing Medical University

Among the 22 studies testing disitamab vedotin in Stomach Neoplasms, this one is the 16th largest by planned enrollment, is one of 6 that started in 2024, is one of 15 in phase 2, reaches primary completion later than 12 of the 16 other live ones, and was the 17th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

14 of the 22 studies testing disitamab vedotin in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About disitamab vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing disitamab vedotin in Stomach Neoplasms, or all of them as a file.
02

Study summary

This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery. The study drugs include RC48, Adebrelimab, Apatinib and S-1. The purpose is to evaluate the effectiveness and safety of the combined coordinated treatment of multi-mechanism drugs for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.

Read the detailed description

The study plans to enroll 32 subjects. After signing the informed consent form and meeting the inclusion and exclusion criteria, patients will receive standard-dose treatment of the RC48, Adebrelimab, Apatinib and S-1 regimen for 3-4 cycles (every 3 weeks) before surgery. Apatinib will only be used for 14 days in the last cycle. Imaging studies will be conducted 3-4 weeks after the last dose to assess the efficacy of neoadjuvant therapy and the possibility of radical D2 gastrectomy. The treatment plan after curative surgery for gastric cancer will be determined by the investigators and the patients based on the pathological findings. Patients who benefit clinically after surgery may receive adjuvant therapy with RC48, Adebrelimab, Apatinib and S-1 for 4 cycles (the first treatment is expected to start around 4 weeks after surgery) or follow the standard postoperative adjuvant regimen recommended by the guidelines.

03

Conditions studied

  • Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Participants voluntarily join this study, are able to complete the signing of the form, and have good compliance;
    1. Age between 18 to 75 years old (at the time of signing the informed consent form), with no gender restrictions;
    1. Gastrointestinal cancer or gastroesophageal junction adenocarcinoma confirmed by histology and/or cytology, diagnosed as locally advanced according to the 8th edition of the AJCC standards, with a cTNM diagnosis of T3-4aN+M0 and T4aNanyM0 based on ultrasound endoscopy or enhanced CT/MRI scan (and diagnostic laparoscopy if necessary), and agree to receive curative surgical treatment, with the investigator assessing the potential for tumor resectability;
    1. Have not previously received systemic treatment for the current disease, including anti-tumor chemotherapy/immunotherapy, etc.;
    1. overexpression confirmed by IHC results from endoscopic tissue (defined as: IHC 2+, 3+);
    1. score of 0-1;
    1. Estimated of ≥6 months;
    1. Good major organ function:

Exclusion criteria

Exclusion Criteria:

    1. Concurrent malignant disease other than gastric cancer (excluding early-stage tumors that have been radically treated);
    1. Tumor lesions with a tendency to bleed (such as active ulcerative tumor lesions with positive fecal occult blood test, history of hematemesis or melena within 2 months before signing the form, or assessed by the investigator as being at risk of significant gastrointestinal hemorrhage, etc.) or having received blood transfusion treatment within 4 weeks before the study medication; 3. Inability to take oral medication;
    1. Currently participating in another interventional clinical study treatment, or having received other drugs or used investigational medical devices within 4 weeks before the first administration of the study medication;
    1. Has had systemic treatment required within 2 years before the first administration of the study medication;
    1. Known allogeneic organ transplantation (except for corneal transplantation);
    1. Known allergy to any medication used in this study;
    1. Peripheral neuropathy of grade ≥2;
    1. Known history of (HIV) infection (i.e., positive for HIV 1/2 antibodies);
    1. Active or C infection;
    1. Received within 30 days before the first administration (Day 1 of Cycle 1);
    1. Pregnant or breastfeeding women;
    1. Presence of any severe or uncontrollable systemic disease.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Experimental

    RC48, Adebrelimab, Apatinib and S-1 regimen for 3-4 cycles (every 3 weeks) before surgery.

    Drug: RC48 · Drug: Adebrelimab · Drug: Apatinib · Drug: S-1

Interventions

  • DrugDisitamab vedotinStudies of Disitamab vedotinDisitamab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);

    Also known as: Disitamab Vedotin

  • Adebrelimab:1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);

  • Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);

  • DrugS-1

    Drug pages: TegafurStudies of TegafurTegafur pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GimeracilStudies of GimeracilGimeracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Oxonic AcidStudies of Oxonic AcidOxonic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    S-1:For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);

    Also known as: S-1tegafur, gimeracil and oteracil potassium

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response Rate (pCR)

    Defined as the proportion of subjects with no residual viable tumor cells on microscopy and negative lymph nodes out of the total number of subjects;

    Time frame: 4 months

Secondary outcomes

  1. Major Pathological Response rate (MPR)

    Defined as the proportion of subjects with ≤10% viable tumor cells in the resected specimen out of the total number of subjects;

    Time frame: 4 months

  2. R0 Resection rate

    Complete tumor resection during surgery with negative microscopic margins, meaning no residual tumor;

    Time frame: 4 months

  3. Disease-Free Survival (DFS)

    Defined as the time from enrollment to the first radiological evidence of disease recurrence or death (whichever occurs first)

    Time frame: 24 months

  4. Overall Survival (OS)

    Defined as the time from enrollment to the subject's death from any cause

    Time frame: 36 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for May 2027, 36 months later.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 36 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
Apr 26, 2024
StartEst.
May 1, 2024
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2028
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06385873
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
May 1, 2024 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
May 13, 2024

Study contacts

Xiaofeng Chen, Ph.D
Contact
chenxiaofengnjmu@163.com
13585172066
Hao Xu, Ph.D
Contact
66881866@qq.com
13851530117
Xiaofeng Xiaofeng, Ph.D
principal investigator · The First Affiliated Hospital with Nanjing Medical University
Hao Xu, Ph.D
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion